Humacyte (HUMA) Q2 FY26 earnings call: guidance and Q&A

What were the challenges prior to the commercial rebuild, what specific refinements were made, and what tangible improvements are being observed?

Laura Niklason noted that prior commercial uptake was slower than expected due to underestimation of education challenges and a lack of sales executives with deep vascular surgery connections. Jim Mercadante detailed the rebuild, focusing on hiring individuals with strong vascular surgery relationships, streamlining Value Analysis Committee (VAC) processes, implementing a national account strategy to access more hospitals, and offering introductory pricing incentives. He reported early signs of increased acceptance and uptake.

“One of the key things when you're looking at a technology like this, and this is the reason why I'm here, I believe this technology is going to revolutionize open surgery for sure over time. But you have to have deep vascular surgery relationships. This is a 90% of the call point is vascular surgery for what we're trying to do here.”

asked by Ryan Zimmerman · answered by Jim Mercadante

What steps are being taken to de-risk the sBLA submission, what is the nature of discussions with the FDA, and what are the anticipated timing and launch preparations for ATEV in dialysis access?

Laura Niklason expressed high confidence in the sBLA filing due to multiple FDA discussions, a scheduled pre-BLA meeting focused on file structure, and extensive data from over 1,000 patient-years across three Phase 3 and several Phase 2 studies. The target filing is November, with a request for priority review (supported by RMAT designation) aiming for a May 2027 PDUFA date and an end of Q2 2027 launch. Preparations include significant work on health economics and reimbursement, highlighting cost savings from reduced catheter use.

“Our target right now is that we'll file in November because there is a lot of data to pull together. When we file, we anticipate that we'll ask for a priority review. We anticipate that we should receive a priority review because, again, this is a supplemental BLA and we have multiple priority indications for dialysis access.”

asked by Ryan Zimmerman · answered by Laura Niklason

Details on the sales force size, introductory pricing incentives, streamlining of the VAC process, the number of potential adopting centers, and the commercial strategy for AV access, including Fresenius's role.

Jim Mercadante explained that the VAC process was streamlined through increased flexibility and leveraging KOLs. A national account strategy was implemented to gain access to an additional 1,000 hospitals. Introductory pricing helps surgeons gain experience with the product. He stated that 20 major healthcare systems are currently in the process of adopting Symbest in H2 FY26. For dialysis, the current vascular injury launch is strategically preparing for future dialysis access by establishing Symbest within healthcare systems. Fresenius is one of several strategies for the dialysis launch, with aligned motivations due to their royalty on U.S. vessel sales.

“I can tell you right now, we've got at least 20 major healthcare systems in the U.S. in the process of bringing it into their healthcare systems in the back half of this year.”

asked by Joshua Jennings · answered by Jim Mercadante

How many individual hospitals do the 20 new healthcare systems represent, and was there any slowdown in Q2 sales due to the commercial transition?

Jim Mercadante indicated that the 20 healthcare systems could range from 5 to 50 hospitals each, and adoption typically starts with a few surgeons before expanding. He clarified that Q2 was a rebuilding quarter for the commercial team, and the full impact of the changes would be seen in the back half of the year, with only a minor uptick observed in Q2.

“What you'll see is you'll see those results in the back half. You didn't see them in Q2. That would have been really quick. But we started to see a minor uptick, but the uptick is really in the back half.”

asked by Bruce Jackson · answered by Jim Mercadante

How will the RMAT designation be utilized, what is the desired label language for the dialysis sBLA, what is Fresenius's role given the return of worldwide rights, and does CTEV manufacturing impact ATEV commercial production?

Laura Niklason confirmed RMAT will support the request for priority review for the sBLA. The anticipated label for ATEV in hemodialysis access is for patients at elevated risk of fistula failure, specifically mentioning women and men with risk factors like obesity and diabetes. Fresenius remains a partner, pledged to adopt ATEV as standard of care in their centers, and receives a royalty on all U.S. vessel sales. CTEV manufacturing uses the same machines but requires very low volumes (10 patients for Phase 2a, smallest batch 100 vessels), posing no drain on ATEV commercial production. The CTEV trial is expected to open this month.

“Our anticipated label is that ATEV or [ Symbest ] would be indicated for hemodialysis access in patients who are at elevated risk of fistula failure or non-maturation. And in parentheses, it might say, i.e., women and men with risk factors such as obesity and diabetes.”

asked by Swayampakula Ramakanth · answered by Laura Niklason